NYSE · JNJ
Healthcare · Drug Manufacturers - General
$273.20
Down-$2.00 (-0.73%)
Updated Nov 1, 2026, 1:36 PM
SID Score
8.1/10
Composite research score
Smart Money
50/100
Neutral
Price performance · JNJ
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
JNJ closed at $273.20 after 20 trading sessions, up 8.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $280.00 | $282.015 | $273.13 | $273.20 | 8.97M |
| Oct 29, 2026 | $275.31 | $278.05 | $273.595 | $275.20 | 6.02M |
| Oct 28, 2026 | $265.83 | $272.75 | $264.20 | $271.04 | 6.4M |
| Oct 27, 2026 | $265.25 | $269.09 | $264.83 | $268.73 | 5.77M |
| Oct 26, 2026 | $266.74 | $272.36 | $264.97 | $266.30 | 5.78M |
| Oct 23, 2026 | $265.82 | $266.025 | $262.40 | $263.81 | 5.31M |
| Oct 22, 2026 | $260.54 | $269.67 | $259.04 | $267.61 | 10.13M |
| Oct 21, 2026 | $257.50 | $257.80 | $254.56 | $257.78 | 6.56M |
| Oct 20, 2026 | $257.48 | $260.77 | $256.422 | $259.36 | 7.66M |
| Oct 19, 2026 | $254.43 | $255.56 | $251.50 | $253.79 | 8.85M |
| Oct 16, 2026 | $255.52 | $257.55 | $254.00 | $255.56 | 6.55M |
| Oct 15, 2026 | $257.11 | $262.445 | $252.62 | $253.28 | 9.28M |
| Oct 14, 2026 | $249.095 | $253.94 | $248.50 | $253.91 | 9.66M |
| Oct 13, 2026 | $254.56 | $256.1822 | $245.17 | $248.61 | 16.65M |
| Oct 12, 2026 | $261.60 | $264.39 | $260.3685 | $263.73 | 5.91M |
| Oct 9, 2026 | $255.09 | $261.61 | $254.985 | $261.44 | 5.73M |
| Oct 8, 2026 | $256.22 | $257.80 | $251.945 | $256.48 | 6.18M |
| Oct 7, 2026 | $256.21 | $260.68 | $255.73 | $258.45 | 5.41M |
| Oct 6, 2026 | $254.15 | $255.48 | $251.17 | $254.78 | 5.66M |
| Oct 5, 2026 | $256.00 | $256.24 | $252.51 | $252.93 | 10.03M |
The latest Smart Investors Daily articles mentioning JNJ.
Company
Market Activity
Research & News
JNJ research
Company profile and research snapshot.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | Wells Fargo | Overweight | — |
| Oct 15, 2026 | Morgan Stanley | Overweight | — |
| Oct 14, 2026 | Leerink Partners | Outperform | — |
| Oct 14, 2026 | Wells Fargo | Overweight | — |
| Oct 14, 2026 | RBC Capital | Outperform | — |
Generated Nov 1, 2026, 1:15 PM
Johnson & Johnson shares declined 0.73% ($2.00) today amid mixed quarterly results and segmental challenges. While the company raised its full-year outlook despite taking $7 billion in charges, weakness in its MedTech segment and broader healthcare sector headwinds are tempering investor enthusiasm.
Bottom line: JNJ's mixed Q3 results present a nuanced investment picture: management's ability to raise guidance despite substantial charges is constructive, but MedTech weakness and significant financial charges warrant monitoring. For dividend investors, the stock remains attractive at current levels, though near-term catalysts around Q4 MedTech recovery and new drug progress will be critical to sustained momentum.
Yahoo · Oct 31, 2026
A $600,000 portfolio spread across four blue-chip dividend legends generates a surprisingly large tax bill every year, and the difference between where you hold these shares could quietly reshape your retirement by tens of thousands of dollars.
Yahoo · Oct 31, 2026
Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.
Yahoo · Oct 31, 2026
Five consumer dividend stocks with real 2026 catalysts and the risks that could slow them down are worth a look before the next earnings cycle.
Yahoo · Oct 31, 2026
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article walks through three such biotech stocks screened for balance sheet strength and valuation discipline. The three highlighted biotech stocks are only a sample of what screens well on balance sheet...
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson shares traded at $273.20, reflecting a modest intraday decline of 0.38%, per SID market data. Over the trailing twelve months, JNJ has delivered a gain of approximately $33.40 per share, underscoring sustained upward momentum in the healthcare sector. On a shorter horizon, the stock added $5.62 over the past month and $7.39 over three months. Technically, JNJ trades above both key moving averages, sitting roughly 2.9% above its 50-day moving average of $265.60 and approximately 9.9% above its 200-day moving average of $248.51, according to Massive/Polygon data. The 14-day relative strength index stands at 58.0, positioning the stock in neutral territory without overbought or oversold signals. JNJ's beta of 0.349 confirms its historically low volatility profile relative to the broader market. Average daily trading volume stands at approximately 8.82 million shares, reflecting consistent institutional participation and robust liquidity.
Johnson & Johnson commands a market capitalization of approximately $505.78 billion, positioning it among the largest healthcare companies globally, per SID market data. The stock currently trades at a price-to-earnings ratio of 20.30, which aligns broadly with the large-cap healthcare sector median. Its PEG ratio of 1.91 suggests the market is pricing in moderate earnings growth relative to the current multiple, according to SEC filings. JNJ's price-to-book ratio stands at 6.43, reflecting a premium valuation driven by significant intangible assets including pharmaceutical patents and the MedTech portfolio. The company maintains a dividend yield of approximately 2.45%, continuing its well-established track record as a Dividend King. This yield provides income-oriented investors with a steady return component alongside capital appreciation potential. The valuation metrics collectively indicate that JNJ trades at a premium consistent with its defensive characteristics, diversified revenue streams, and strong balance sheet within the healthcare sector.
Johnson & Johnson's composite smart money score stands at 50 out of 100, reflecting a neutral overall signal, per SID market data. The institutional sub-score registers a perfect 25 out of 25, indicating exceptionally strong conviction among large fund managers and consistent accumulation patterns across major institutional holders, according to 13F institutional filings. In contrast, the insider activity sub-score sits at 8.7 out of 25, with SEC Form 4 filings revealing 16 insider transactions over the past 90 days, comprising 7 purchases and 9 sales. This slight net selling bias among corporate insiders tempers the otherwise strong institutional signal. The dark pool activity sub-score of 9.5 out of 25 suggests below-average block trading volume through alternative venues. Congressional trading activity scores 7.0 out of 25, reflecting limited recent legislative member transactions in JNJ shares. The divergence between maximum institutional confidence and modest insider selling creates a mixed but broadly balanced smart money profile for the company, warranting continued monitoring of Form 4 disclosures for directional shifts.
Johnson & Johnson has demonstrated a consistent pattern of meeting or exceeding analyst expectations across recent quarters, according to company earnings reports. In the most recent quarter reported on October 13, JNJ posted earnings per share of $2.59 versus a consensus estimate of $2.53, delivering a positive surprise of $0.06. The prior quarter saw EPS of $2.90 against estimates of $2.85, a $0.05 beat. The April quarter similarly produced a modest outperformance with actual EPS of $2.70 compared to the $2.67 estimate. The only miss in the four-quarter sequence occurred in January, when JNJ reported $2.46 versus the $2.47 consensus, a negligible shortfall of one cent, per analyst estimates. The sequential EPS trajectory from $2.46 to $2.59 across the four reported periods reflects underlying earnings stability. JNJ's ability to consistently deliver near or above consensus reinforces its reputation as a predictable earnings compounder within the healthcare sector.
Wall Street coverage of Johnson & Johnson reflects a broadly constructive consensus, with multiple major firms reiterating positive ratings in October 2026, per Wall Street analyst reports. Wells Fargo maintained its Overweight rating on two separate occasions, on October 14 and October 16, signaling sustained conviction in the stock's risk-reward profile. Morgan Stanley similarly reiterated its Overweight rating on October 15, aligning with the bullish institutional view. Leerink Partners maintained an Outperform rating on October 14, while RBC Capital also reiterated Outperform on the same date, according to SID consensus data. Notably, all five most recent analyst actions represent reiterations rather than upgrades or downgrades, suggesting stable sentiment rather than a shifting outlook. The clustering of these reiterations around mid-October coincides with the company's latest earnings release, indicating that quarterly results reinforced existing positive theses. No recent downgrades or bearish initiations appear among major coverage firms, underscoring the prevailing Wall Street confidence in JNJ's fundamental trajectory.
The latest Smart Investors Daily articles mentioning JNJ.
